Search results for "Tipiracil"

showing 2 items of 12 documents

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study

2020

Background: TAS-102 is an oral monotherapy, combining trifluridine and tipiracil hydrochloride, indicated for the treatment of pretreated metastatic colorectal cancer (mCRC). The aim of this real-life study is to evaluate the efficacy and safety of TAS-102 in heavily pretreated elderly patients with mCRC whose disease has progressed with standard therapies. Methods: In this retrospective observational study, we enrolled 50 elderly patients >70 years of age (median age 78 years) with a diagnosis of mCRC who were previously treated or were not considered candidates for treatment with other available therapies. Patients aged >70 years with advanced colorectal cancer and with an ECOG perf…

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentTrifluridineECOG Performance StatusDiseasechemotherapyelderly patientstrifluridine/tipiracilQuality of lifeInternal medicinemedicinelonsurfOriginal ResearchPharmacologyChemotherapybusiness.industrymetastatic colorectal cancertrifluridine/ tipiracillcsh:RM1-950Retrospective cohort studyGeneral Medicinemedicine.diseaselcsh:Therapeutics. PharmacologyTolerabilityquality of lifetas-102Molecular Medicinebusinessmedicine.drugDrugs in Context
researchProduct

Late-line treatment in metastatic gastric cancer: today and tomorrow.

2019

Survival for patients with unresectable advanced or recurrent gastric cancer (GC) remains poor and the historical lack of evidence-based therapeutic options after second-line therapy is reflected in current clinical guidelines for this condition. Despite uncertainty about optimal therapeutic strategies, further treatment is appropriate for some patients after failure of second line and may prolong survival. This approach has been reported in clinical trials and is becoming more common in real-world clinical settings. Several prognostic factors may increase the likelihood that a patient will be eligible for treatment in the third-line setting, including geographic location, status at diagno…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPopulationPembrolizumabReviewchemotherapylcsh:RC254-282law.inventiontrifluridine/tipiracilchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineeducationTipiracilnivolumabChemotherapyeducation.field_of_studybusiness.industryImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensClinical trialgastric cancer (GC)OncologychemistryimmunotherapypembrolizumabNivolumabbusinessTherapeutic advances in medical oncology
researchProduct